Hypertension - Pipeline Review, H1 2014: 48 Conipanies and 94 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h24nbf/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Companies Involved: - AFFiRiS AG - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Ahn-Gook Pharmaceutical Co., Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - Anacor Pharmaceuticals, Inc. - AngioDesign - Arromax Pharmatech, Co. Ltd. - Bayer AG - BioLineRx, Ltd. - Biocon Limited - Biolink Group AS - CJ CheilJedang Corp. - Cellceutix Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - Cyano Biotech GmbH - Cytokinetics, Incorporated - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - NanoForm Therapeutics Ltd. - Novartis AG - Palatin Technologies, Inc. - QUANTUM GENOMICS Corp. - RedHill Biopharma Ltd. - Sanofi - Takeda Pharmaceutical Company Limited - Toray Industries, Inc. - Torrent Pharmaceuticals Limited Drug Profiles: - azilsartan medoxomil - carvedilol CR - (rosuvastatin telmisartan) - (irbesartan atorvastatin calcium) - (rosuvastatin calcium olmesartan medoxomil) - ZV Combi - pratosartan - carvedilol CR - (rosuvastatin calcium olmesartan medoxomil) - (rosuvastatin valsartan) - CKD-825 - (losartan potassium hydrochlorothiazide amlodipine besylate) - XY-1014-KD-2 - PL-3994 - (atorvastatin calcium losartan potassium) - KD-027 - CS-3150 - (simvastatin Immediate Release amlodipine maleate Delayed Release) - LFF-269 - Potassium Magnesium Citrate - pratosartan - dextromethorphan - QGC-001 - HPT-C/D-3G - (amlodipine besylate losartan potassium) - (simvastatin losartan potassium) - (simvastatin Immediate Release amlodipine maleate Delayed Release) - (candesartan amlodipine besylate) - TAK-272 - MK-7145 IR For more information visit http://www.researchandmarkets.com/research/h2...pertension
Cytokinetics, Incorporated Reports First Quarter 2014 Financial Results
Thomson Reuters ONE - Tue May 06, 3:03PM CDT
Company Considers Potential Next Steps for First-in-Class Skeletal Muscle Activator Focused to ALS
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Clinical Winners and Losers: Spectrum Pharmaceuticals and Cytokinetics
Cory Renauer, The Motley Fool - Motley Fool - Fri May 02, 8:30AM CDT
Clinical trial highlights took a back seat last week to the stream of blockbuster deals in the health care sector. Still, there was a big winner and a big loser -- even if they flew relatively under the radar. Spectrum Pharmaceuticals was, in my...
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Dueling Analysts on Cytokinetics: ALS Drug is 'Finished' or a 'Ray of Sunshine'
at The Street - Tue Apr 29, 10:24AM CDT
Two sell-side analysts with very different views Tuesday on Cytokinetics and its experimental ALS drug tirasemtiv.
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
Cytokinetics Announces Additional Results from BENEFIT-ALS
Thomson Reuters ONE - Tue Apr 29, 6:31AM CDT
First Clinical Trial in Patients with ALS to Show a Significant Reduction in Decline of Slow Vital Capacity
Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.
Hot Stock: Cytokinetics, Shares Drop 5.3% (CYTK)
Comtex SmarTrend(R) - Mon Apr 28, 10:11AM CDT
Cytokinetics (NASDAQ:CYTK) is one of today's worst performing low-priced stocks, down 5.3% to $4.35 on 1.6x average daily volume. Thus far today, Cytokinetics has traded 1.9 million shares, vs. average volume of 1.2 million shares per day. The stock has underperformed the Dow (-5.3% to the Dow's 0.7%) and underperformed the S&P 500 (-5.3% to the S&P's 0.5%) during today's trading.
This Week in Biotech: Is This the Return of Big M&A?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 26, 2:15PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Cytokinetics (CYTK) Stock Is Plummeting Today (Update)
at The Street - Fri Apr 25, 3:20PM CDT
Cytokinetics (CYTK) plummeted more than 60% to a one-year low of $4.96 on Friday after the biotechnology company announced its experimental treatment for Lou Gehrig's disease failed to meet its primary goal in a mid-stage trial.
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 25, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why Cytokinetics Inc. Shares Were Mauled
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 25, 12:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cytokinetics , a clinical-stage...
Is There Value In Cytokinetics Following Its 60% Drop?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 25, 10:50AM CDT
Big money can be made in owning promising pipelines, but only if trial data validates the hope. In the case of Cytokinetics , hope was dashed when the company reported its drug for ALS, also known as Lou Gehrig's Disease, failed to meet its primary...
Cytokinetics skids after ALS drug fails in study
AP - Fri Apr 25, 10:02AM CDT
NEW YORK (AP) — Shares of Cytokinetics lost more than half their value Friday after the drug developer said an experimental treatment for Lou Gehrig's disease failed to slow the fatal condition's progression more than a placebo in a clinical trial.
Cytokinetics Announces Top-Line Results From BENEFIT-ALS
Thomson Reuters ONE - Fri Apr 25, 6:31AM CDT
Company Summarizes Initial Data From Phase IIb Clinical Trial of Tirasemtiv
Cytokinetics to Announce First Quarter Results on May 6, 2014
Thomson Reuters ONE - Thu Apr 24, 3:40PM CDT
South San Francisco, CA., April 24, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report first quarter results on Tuesday, May 6, 2014 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.